NASDAQ:ZVSA
ZyVersa Therapeutics, Inc. Stock News
$4.94
+0.86 (+21.08%)
At Close: May 31, 2024
Research demonstrated that activation of the inflammasome/ASC speck pathway has a vital role in synaptic degeneration in Alzheimer's Disease (AD). ZyVersa is developing IC 100, a monoclonal antibody t
ZyVersa Therapeutics Highlights Peer-Reviewed Article Linking Inflammasome Activation to Triple-Negative Breast Cancer Brain Metastasis
07:52am, Wednesday, 17'th Jan 2024
Up to 40% of women with triple negative breast cancer (TNBC) experience metastasis to their brain, which affects physical function, independence, personality, quality of life, and significantly increa
ZyVersa Therapeutics' CEO, Stephen C. Glover, Featured on Benzinga All Access
08:06am, Wednesday, 10'th Jan 2024
WESTON, Fla., Jan. 10, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treat
ZyVersa Therapeutics Announces Equity Research Coverage Initiated by Noble Capital Markets
07:50am, Thursday, 04'th Jan 2024
WESTON, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treat
ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Providing Outlook for 2024
08:07am, Wednesday, 03'rd Jan 2024
WESTON, Fla., Jan. 03, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treat
Why Is ZyVersa Therapeutics (ZVSA) Stock Down 44% Today?
09:07am, Thursday, 07'th Dec 2023
ZyVersa Therapeutics (NASDAQ: ZVSA ) stock is sliding lower on Thursday after the clinical-stage biopharmaceutical company priced a public share offering. ZyVersa Therapeutics is offering 4 million s
Why Is ZyVersa Therapeutics (ZVSA) Stock Up 27% Today?
09:54am, Wednesday, 06'th Dec 2023
ZyVersa Therapeutics (NASDAQ: ZVSA ) stock is rising higher on Wednesday after the clinical-stage specialty biopharmaceutical company highlighted the publication of a paper in a peer-reviewed journal.
Why Is ZyVersa Therapeutics (ZVSA) Stock Down 46% Today?
08:51am, Wednesday, 26'th Apr 2023
ZyVersa Therapeutics (NASDAQ: ZVSA ) stock is sliding lower on Wednesday following a couple of announcements from the company. The first is the company's publication of an article in the peer-reviewe
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Present at Planet MicroCap Showcase
09:07am, Tuesday, 11'th Apr 2023
WESTON, Fla., April 11, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for t
Why Is ZyVersa Therapeutics (ZVSA) Stock Up 35% Today?
08:08am, Thursday, 23'rd Mar 2023
ZyVersa Therapeutics (NASDAQ: ZVSA ) stock is taking off on Thursday without any recent news from the biopharmaceutical company. Instead, it looks like investors can thank heavy pre-market trading for
Why Is ZyVersa Therapeutics (ZVSA) Stock Up 94% Today?
08:08am, Thursday, 02'nd Feb 2023
ZyVersa Therapeutics (NASDAQ: ZVSA ) stock is flying higher on Thursday as investors react to a preliminary prospectus for a stock offering. The stock offering announced by ZyVersa Therapeutics covers
ZyVersa Therapeutics to Present at BIO CEO & Investor Conference
09:45am, Wednesday, 25'th Jan 2023
WESTON, Fla., Jan. 25, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for th
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Present at the Virtual Investor 2023 Companies to Watch Event
02:45pm, Wednesday, 11'th Jan 2023
Live video webcast on Wednesday, January 18th at 2:00 PM ET
